ArticleOncotarget2016

Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.

Yonghua Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.